Tissue-resident Immune Cell Subsets in aGVHD — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Tissue-resident Immune Cell Subsets in aGVHD — Stella

Recruiting

Back to Acute Graft-versus-Host Disease trials

Trial locations(1 site)

China

Nanfang Hospital, Southern Medical University, Guangzhou, Other (Non U.s.)

Key details

Sponsor

Nanfang Hospital, Southern Medical University

Enrollment target

~40 participants

Started

November 2024

Primary completion

February 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 65 Years

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov